News

Bluebird Hits $3m Mark With Gene Therapy After FDA Approval

Within one firm, the title of most costly treatment in the world has changed hands within a month. Bluebird Bio has received an FDA fast clearance for Skysona, also known as eli-cel, for the uncommon neurological condition cerebral adrenoleukodystrophy (CALD),...

First Next-Gen Parkinsons Med To Be Made By Neuron23, QIAGEN

QIAGEN and Neuron23TM Inc., an early-stage biotechnology company focused on creating precision medications for genetically defined neurological and immunological illnesses, have announced a partnership to create a companion diagnostic for Neuron23's LRRK2 inhibitor for Parkinson's disease. According to the terms...

Australia Permits New Treatment For Rare Bile Duct Cancer

Australia has authorised the use of a new targeted therapy for the treatment of cholangiocarcinoma, a rare bile duct cancer. The Therapeutic Goods Administration (TGA) has granted PEMAZYRE (pemigatinib) provisional approval for the treatment of adult patients with metastatic...

Beyfortus From Sanofi And Astrazeneca Is Supported By RSV

Beyfortus has received approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency to treat lower respiratory tract sickness caused by the respiratory syncytial virus (RSV) in neonates and young children. If authorised, Beyfortus,...

canSERV, EU Cluster Effort, Offers Cancer Study In Europe

Brussels marks the beginning of the European canSERV initiative, which aims to defragment the European cancer research landscape. CanSERV will give academia and business exposure to cross-cutting services and assistance from fundamental science up to clinical application over the...

WHO Strongly Advises Against The Use of 2 COVID Therapies

The World Health Organization (WHO) has discontinued the use of two COVID-19 antibody treatments on the grounds that Omicron and the variant's most recent offspring have probably made them ineffective. The two treatments were among the first drugs created in...

Day 1- CONNECT IN PHARMA, Geneva, Switzerland

Happiness can never be stalled, and that was pretty evident on Day 1 of Connect in Pharma. To advance innovation in a cooperative setting, Connect in Pharma has brought together specialists in the pharmaceutical and biotech industries under one...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read